©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Dec 16, 2022; 10(35): 12959-12970
Published online Dec 16, 2022. doi: 10.12998/wjcc.v10.i35.12959
Published online Dec 16, 2022. doi: 10.12998/wjcc.v10.i35.12959
Comparative effectiveness of first-line therapies for eradication of antibiotic-resistant Helicobacter pylori strains: A network meta-analysis
Shu-Peng Zou, Qian Cheng, Cheng-Yang Feng, Chan Xu, Ming-Hui Sun, Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, Hubei Province, China
Author contributions: Zou SP and Cheng Q performed the research as well as screening, inclusion, and exclusion of randomized controlled trials, and wrote the paper; Sun MH designed the study; Feng CY and Xu C reviewed the data extracted from the study.
Conflict-of-interest statement: All the authors disclose no conflicts of interest for this paper.
PRISMA 2009 Checklist statement: The scheme of the study was successfully registered at PROSPERO (registration number: 42022326460).
Corresponding author: Ming-Hui Sun, PhD, Professor, Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No.1095 Jiefang Avenue, Wuhan 430000, Hubei Province, China. tjzoushupeng@163.com
Received: August 16, 2022
Peer-review started: August 16, 2022
First decision: September 26, 2022
Revised: October 8, 2022
Accepted: November 30, 2022
Article in press: November 30, 2022
Published online: December 16, 2022
Processing time: 120 Days and 3 Hours
Peer-review started: August 16, 2022
First decision: September 26, 2022
Revised: October 8, 2022
Accepted: November 30, 2022
Article in press: November 30, 2022
Published online: December 16, 2022
Processing time: 120 Days and 3 Hours
Core Tip
Core Tip: This is the first study to compare currently available first-line treatment regimens for eradication of antibiotic-resistant Helicobacter pylori strains. For clarithromycin-resistant and metronidazole-resistant strains, dual therapy containing a high-dose proton pump inhibitor (HDDT) shows an absolute advantage over other first-line therapies. There was a difference in the effectiveness of HDDT between all patients and patients with clarithromycin-resistant Helicobacter pylori infection. In the subgroup of high cure rates (≥ 90%), HDDT was also generally better than other therapies. The use of fewer antibiotics may be better to prevent global antibiotic resistance effectively.